They found a high efficiency of CTC capture in 10 RCC patients from the integrated approach of the NanoVelcro platform with anti-CAIX and anti-CD147 antibodies, compared to technology using the EpCAM marker only. Here, CA9 is linked to renal cell carcinoma.